| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 28,773 | 30,549 | ||
| General and administrative | 7,898 | 8,515 | ||
| Total operating expenses | 36,671 | 39,064 | ||
| Loss from operations | -36,671 | -39,064 | ||
| Other income, net | 4,084 | 2,709 | ||
| Net loss | -32,587 | -36,355 | ||
| Unrealized gain on investments | 428 | -22 | ||
| Comprehensive loss | -32,159 | -36,377 | ||
| Net loss per share, basic | -0.33 | -0.47 | ||
| Net loss per share, diluted | -0.33 | -0.47 | ||
| Weighted-average shares outstanding, basic | 98,953,331 | 78,126,257 | ||
| Weighted-average shares outstanding, diluted | 98,953,331 | 78,126,257 | ||
Oric Pharmaceuticals, Inc. (ORIC)
Oric Pharmaceuticals, Inc. (ORIC)